Client & Alumni News
Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic tests that individually optimize a patient’s exposure to chemotherapy, today announced that Saladax Biomedical Laboratories (SBL) has received its licenses from the state-specific Departments of Health for California, Rhode Island and Maryland.
“The SBL CLIA laboratory operations are at the heart of our U.S. commercialization plan that will include an expanding suite of MyCare exposure optimization tests that we believe give cancer patients and their medical team another tool to assist with personalizing their therapy,” said Mark D. Myslinski, SVP and Chief Commercial Officer at Saladax Biomedical, Inc.
Read more.
